Recombinant human type III collagen, gene, expression vector, bacteria and application
Patent Information
- Application Number
- CN202410540162.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-04-30
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2044-04-30
Smart Images

Figure CN118255873B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of bioengineering technology, and in particular to a recombinant human type III collagen protein and its gene, expression vector, bacteria and application. Background Art
[0002] Collagen is the most abundant structural protein in the human body. It has special biological functions and provides important mechanical properties in tissues, including elasticity and toughness. Therefore, collagen-related biomaterials are mostly used for tissue repair and regeneration. In recent years, due to the development of social economy, the market demand for collagen has gradually increased. The earliest extraction methods of collagen are mostly to extract it from "animal tissue" using acid or alkaline hydrolysis. The heterologous extraction method has obvious disadvantages, including strong immune rejection reactions, potential viruses, infectious diseases and other safety hazards. Human collagen has weak antigenicity, can induce cell proliferation, migration and promote cell adhesion, and is an important and safe biomaterial.
[0003] Type III human collagen is a fibrillar collagen secreted by fibroblasts and interstitial cells, a homotrimer formed by three α1(Ⅲ) chains (COL3A1). In terms of pathology, type III collagen is associated with inflammation in the body, such as lung damage, viral and non-viral liver disease, renal fibrosis, hernia and vascular-related diseases. Mutations in type III collagen may lead to congenital connective tissue dysplasia syndrome, vascular defects, and aortic and aneurysm. In the field of skin care, the content of type III collagen in the skin will gradually decrease with age, so many cosmetics and medical beauty products supplement collagen to the skin to achieve the purpose of moisturizing and wrinkle removal. Type III collagen has many potential applications in the market, such as using type III collagen as a material to make artificial corneas, artificial heart valves, and endometrial repair; using type III collagen as a drug, adding it to cancer tissue can promote cancer cells to enter and maintain a dormant state and inhibit tumor proliferation. Based on the above, type III collagen has a huge application market.
[0004] However, although type III collagen has a huge application market, there is currently insufficient research on highly active collagen fragments.
[0005] With the development of genetic engineering technology, expression systems based on animals, plants and microorganisms have gradually been established, among which microbial expression systems have been studied most extensively. Li Jia et al. used the Bacillus expression system to obtain a human type III collagen peptide containing a non-helical region N segment, a non-helical region C segment and a 100% human collagen fragment by splicing and recombination (China Patent Authorization No. CN114539390B), but the Bacillus expression system has defects such as low promoter transcription level, easy decomposition of the expression product, and toxic and expensive inducers. Yang Xia et al. used Escherichia coli to express human collagen type III peptide (China Patent Authorization No. CN103122027B), and Fan Daidi's research group expressed a type III collagen protein through Escherichia coli (China Patent Authorization No. CN115991763A), but the Escherichia coli expression system still faces some difficult problems. The produced collagen has endotoxins, complex purification steps, and lack of post-translational modifications, which increases production costs. In contrast, the Pichia pastoris expression system is increasingly being used to express highly active recombinant collagen due to its advantages such as high yield, no endotoxin, simple purification, low cost, and ability to perform post-translational modification. Therefore, it is possible to attempt to construct a human type III collagen expression system based on Pichia pastoris.
[0006] At the same time, integrin is a transmembrane receptor, a heterodimer formed by two subunits, α and β, which can mediate signal transmission in the intracellular and extracellular environment and respond quickly and sensitively to changes in the environment. Therefore, in addition to the mechanical action of passing through the membrane, integrin is also involved in cell messaging, cell cycle regulation, cell morphology and cell movement. The amino acid sequences of integrin recognition sites include GER, GEK, etc. Collagen fragments containing the corresponding amino acid sequences and with the sites exposed to the outside can be recognized by integrins on the cell membrane and promote cell-related functions through signal transduction. Therefore, on the basis of human type III collagen, recombinant human type III collagen with better biological activity can be obtained through sequence design and optimization based on integrin recognition sites. Summary of the invention
[0007] The technical problem to be solved by the present invention is to provide a recombinant human type III collagen protein and gene, expression vector, bacteria and application. The obtained recombinant human type III collagen protein fragment has a small molecular weight and excellent activity. It not only has an excellent effect of promoting cell proliferation in mouse embryonic fibroblasts, but also has an excellent effect of promoting cell proliferation and migration in human immortalized epidermal cells. It can be widely used in wound repair materials, medical cosmetic surgery, cosmetics, health care products and other fields.
[0008] The present invention adopts the following technical solutions to solve the above technical problems:
[0009] A recombinant human type III collagen, the amino acid sequence of which is shown in SEQ ID NO.2.
[0010] The recombinant human type III collagen fragment provided by the present invention has a small molecular weight, contains two GER and one GEK integrin recognition sites, has excellent activity, and has an excellent effect of promoting cell proliferation not only in mouse embryonic fibroblasts, but also in human immortalized epidermal cells, and has an excellent effect of promoting cell proliferation and migration. It can be widely used in wound repair materials, medical cosmetic surgery, cosmetics, health care products and other fields.
[0011] A recombinant human type III collagen encoding gene, wherein the gene encodes the recombinant human type III collagen according to claim 1, and the nucleotide sequence is shown in SEQ ID NO.1.
[0012] As one of the preferred embodiments of the present invention, the nucleotide sequence shown in SEQ ID NO.1 is a codon-optimized sequence adapted to the Pichia pastoris expression system.
[0013] As one of the preferred embodiments of the present invention, online codon optimization software is used to change the corresponding original recombinant human type III collagen codon bases to the bases preferred by Pichia pastoris codons without changing the protein coding sequence.
[0014] An expression vector comprises the above-mentioned recombinant human type III collagen encoding gene.
[0015] As one of the preferred embodiments of the present invention, the method for constructing the expression vector is as follows: adding an EcoRI restriction site sequence to the 5' end of the coding gene sequence, and adding a stop codon and a NotI restriction site sequence to the 3' end; then, inserting the sequence fragment into the pPIC9K expression vector through the EcoRI and NotI restriction sites to obtain the corresponding recombinant expression vector.
[0016] A recombinant Pichia pastoris engineered bacterium comprises the above-mentioned recombinant human type III collagen coding gene.
[0017] As one of the preferred embodiments of the present invention, the construction method of the engineered bacteria is as follows: the expression vector constructed by the recombinant human type III collagen encoding gene is linearized and then transferred into Pichia pastoris GS115.
[0018] A method for preparing the above-mentioned recombinant human type III collagen comprises the following steps:
[0019] (1) synthesizing the nucleotide sequence encoding a recombinant human type III collagen single chain as shown in SEQ ID NO.1;
[0020] (2) Designing PCR primers to amplify a DNA fragment encoding a single-chain recombinant human type III collagen, wherein the primers are shown in SEQ ID NO.3 and SEQ ID NO.4;
[0021] (3) constructing a recombinant expression vector comprising the DNA fragment encoding the recombinant human type III collagen single chain, wherein the expression vector is pPIC9K;
[0022] (4) After linearization, the constructed expression vector was transformed into Pichia pastoris GS115 to obtain recombinant Pichia pastoris engineered bacteria;
[0023] (5) culturing the above-mentioned recombinant Pichia pastoris engineered bacteria to express recombinant human type III collagen fragment;
[0024] (6) Separation and purification of the recombinant human type III collagen fragment expressed in step (5): separation and purification of the recombinant type III collagen was performed using dialysis (dialysis fluid: 10 mM sodium acetate, pH 4.5), ion exchange, and secondary dialysis (dialysis fluid: PBS, pH 7.0).
[0025] An application of the above recombinant human type III collagen in the fields of wound repair materials, medical cosmetology and plastic surgery, cosmetics, and health care products.
[0026] The advantages of the present invention compared to the prior art are:
[0027] (1) The recombinant human type III collagen fragment provided by the present invention has a small molecular weight, contains two GER and one GEK integrin recognition sites (the GER and GEK sites can be recognized by the integrin recognition sites on the cell membrane, and then transmitted to the cells through signal transduction to promote cell proliferation and adhesion), has excellent activity, and has an excellent effect of promoting cell proliferation not only in mouse embryonic fibroblasts, but also in human immortalized epidermal cells. It also has an excellent effect of promoting cell proliferation and migration, and can be widely used in the fields of wound repair materials, medical cosmetic surgery, cosmetics, health care products, etc., especially has good application prospects in skin damage;
[0028] (2) According to the expression characteristics of Pichia pastoris, the present invention also performs codon optimization on the nucleotide sequence encoding the recombinant human type III collagen, so that the nucleotide sequence encoding the recombinant human type III collagen is more suitable for the expression system of Pichia pastoris, and finally screens a strain of recombinant human type III collagen high-yield strain through liquid small-scale expression;
[0029] (3) The present invention combines “dialysis and ion exchange chromatography” for purification, thereby obtaining high-recovery and high-purity recombinant human type III collagen;
[0030] (4) The present invention uses Pichia pastoris as a host to produce recombinant human type III collagen, which can fully support the biological functions of the collagen products produced by this collagen;
[0031] (5) The pPIC9K used in the present invention is an expression vector that can continuously secrete and express collagen during the life activities of the engineered bacteria. The fermentation process is simple and contains few impurities, thus providing an advantageous strain for large-scale fermentation production. BRIEF DESCRIPTION OF THE DRAWINGS
[0032] Figure 1 It is a diagram showing the active sites of GER and GEK in the amino acid sequence of recombinant human type III collagen COLIII-20 in Example 1;
[0033] Figure 2 This is the agarose gel electrophoresis diagram of the DNA fragment of the recombinant human type III collagen COLIII-20 in Example 1 (in the figure, M is a marker, lanes 1 and 2 are samples; the target band size is 627 bp);
[0034] Figure 3 The electrophoresis diagram of the protein obtained by separation and purification of the recombinant human type III collagen COLIII-20 in Example 4 (in the figure, the first lane is the molecular weight marker, the second, third and fourth lanes are the impurity proteins, and the fifth lane is the target protein; the molecular weight of the COLIII-20 protein detected by electrophoresis is about 20 kDa, corresponding to the protein containing the amino acid sequence of SEQ ID NO.2);
[0035] Figure 4 Graph showing the effect of recombinant human type III collagen COLIII-20 on the proliferation of mouse embryonic fibroblasts and human immortalized epidermal cells in Example 5 (Figure A shows the effect on mouse embryonic fibroblasts NIH / 3T3, and Figure B shows the effect on human immortalized epidermal cells HaCaT);
[0036] Figure 5 This is a graph showing the effect of recombinant human type III collagen COLIII-20 on the migration rate of human immortalized epidermal cells in Example 5;
[0037] Figure 6 This is a curve chart of the fermentation bacterial growth and target protein expression level of the recombinant human type III collagen COLIII-20 in Example 6 in a 5L fermenter. DETAILED DESCRIPTION
[0038] The following is a detailed description of an embodiment of the present invention. This embodiment is implemented on the premise of the technical solution of the present invention, and a detailed implementation method and a specific operation process are given, but the protection scope of the present invention is not limited to the following embodiment.
[0039] The Pichia pastoris GS115 strain and expression vector pPIC9K used in the following examples are both strains and vectors that can be directly purchased. The medium formula used is as follows:
[0040] 1) YPD complete medium:
[0041] Prepare 1L, add 10g / L yeast extract and 20g / L peptone to 900mL water, sterilize by high pressure, and then add 100mL sterile 10× glucose solution. The solid medium contains 1.5% agar.
[0042] 2) MD medium:
[0043] To prepare 1L, first autoclave 800mL of water, cool to 60°C, then add 100mL 10X YNB, 2mL 500X biotin, and 100mL 10X glucose. The solid medium contains 2% agar.
[0044] 3) BMGY medium:
[0045] Prepare 1L, add 10g / L yeast extract and 20g / L peptone to 700mL water, sterilize by autoclave, cool to room temperature, then add 100mL 1M potassium phosphate buffer (pH 6.0), 100mL 10X YNB, 2mL 500X biotin, and 100mL 10X glycerol.
[0046] 4) BMMY medium:
[0047] Prepare 1L, add 10g / L yeast extract and 20g / L peptone to 700mL water, sterilize by autoclave, cool to room temperature, then add 100mL 1M potassium phosphate buffer (pH 6.0), 100mL 10X YNB, 2mL 500X biotin, and 100mL 10X methanol.
[0048] 5) BSM medium:
[0049] CaSO4 0.93g / L, K2SO4 18.2g / L, MgSO4·7H2O 14.9g / L, KOH 4.13g / L, glycerol 40g / L, defoaming agent 1g / L, add 26.7mL of 85% phosphoric acid after sterilization.
[0050] 6) PTM1 trace elements:
[0051] CuSO4·5H2O 6g / L, NaI 0.08g / L, MnSO4·H2O 3g / L, NaMoO4·2H2O 0.2g / L, H3BO30.02g / L, CoCl2 0.5g / L, ZnCl2 20g / L, FeSO4·7H2O 65g / L, biotin 0.2g / L, H2SO4 5mL.
[0052] Meanwhile, the DMEM basal culture medium, PBS, fetal bovine serum (FBS), and trypsin used in the following examples are from Vivacell, and the calf serum (BCS), mouse embryonic fibroblast cell line NIH / 3T3, and human immortalized epidermal cell line HaCaT are from Oricell.
[0053] Example 1
[0054] Recombinant human type III collagen COLIII-20 encoding gene:
[0055] In this example, the optimized recombinant human type III collagen COLIII-20 coding gene was finally screened, and its nucleotide sequence is shown in SEQ ID NO.1, and the corresponding amino acid sequence is shown in SEQ ID NO.2 (the GER and GEK active sites in the amino acid sequence of recombinant human type III collagen COLIII-20 are shown in Figure 1 ).
[0056] Gene screening optimization process:
[0057] (1) Based on the human type III collagen gene sequence in GeneBank, an original sequence fragment containing two GER and one GEK integrin recognition site sequences was found, as shown in SEQ ID NO.3.
[0058] (2) Based on the codon preference of Pichia pastoris and the AT content of the DNA sequence, online codon optimization software was used to change the corresponding original recombinant human type III collagen codon bases to the bases preferred by Pichia pastoris codons without changing the protein coding sequence. The optimized gene sequence is shown in SEQ ID NO.1; the optimized gene sequence was artificially synthesized by Shanghai Shenggong Biotechnology Co., Ltd.
[0059] Gene cloning:
[0060] Specific primers were designed and PCR was used to amplify a DNA fragment encoding a single-stranded recombinant human type III collagen COLIII-20. The PCR system is shown in Table 1.
[0061] Table 1 PCR amplification reaction system and reaction conditions
[0062]
[0063] 1% agarose gel electrophoresis was used to detect the target fragment. The results were as follows Figure 2 As shown (target band size is 627 bp).
[0064] Example 2
[0065] Construction of recombinant human type III collagen COLIII-20 expression vector:
[0066] An EcoRI restriction site sequence was added to the 5' end of the coding gene sequence, and a stop codon and NotI restriction site sequence were added to the 3' end; subsequently, the sequence fragment was inserted into the pPIC9K expression vector through the EcoRI and NotI restriction sites to obtain the corresponding recombinant expression vector pPIC9K-COLIII-20.
[0067] Example 3
[0068] Construction of recombinant Pichia pastoris engineering bacteria:
[0069] (1) The successfully constructed recombinant expression vector plasmid pPIC9K-COLIII-20 was linearized and then transferred into the competent cell of Pichia pastoris GS115.
[0070] (2) Single clones were picked from the transformed MD plate and placed in a 48-well culture plate containing 500 μL YPD (0.75 mg / mL G418) medium. The plates were cultured at 30°C and 240 rpm for 18–24 h. The plates were then transferred to YPD liquid medium with increasing G418 content.
[0071] (3) Fermenting the strain with good growth, the steps are as follows:
[0072] Inoculate the bacterial solution into 10mL / 50mL BMGY at a 2% inoculum volume and culture at 30°C, 240rpm for 18-24h;
[0073] After centrifugation, the supernatant was discarded and 10 mL of BMMY was added for resuspending. The cells were cultured at 28°C, 240 rpm for 48 h, and 100% methanol was added every 24 h to a final concentration of 1.5%;
[0074] The mixture was centrifuged and the supernatant was taken for SDS-PAGE analysis to obtain the recombinant Pichia pastoris with high expression level.
[0075] Example 4
[0076] Production, preparation and purification of recombinant human type III collagen COLIII-20:
[0077] (1) The successfully constructed recombinant Pichia pastoris (glycerol strain) was activated in YPD (G418 containing corresponding resistance) medium at 30°C, 240 rpm, for 18 h;
[0078] (2) 2% inoculum was transferred to 200 mL / 1 L of BMGY and cultured at 30°C, 240 rpm for 26-28 h to completely consume the glycerol in the culture medium;
[0079] (3) Take 200 mL of BMMY to resuspend the cells and culture at 25°C, 240 rpm for 48 h; add 100% methanol every 24 h to a final concentration of 1.5%.
[0080] (4) After fermentation, the supernatant was filtered through a 0.22 μm water filter membrane to obtain a clarified fermentation supernatant, which was then separated and purified by dialysis (dialysis fluid: 10 mM sodium acetate, pH 4.5), ion exchange chromatography, and secondary dialysis (dialysis fluid: PBS, pH 7.0).
[0081] Figure 3 This is the protein electrophoresis diagram of the recombinant human type III collagen COLIII-20 separated and purified. The separated and purified COLIII-20 protein solution was analyzed by gel filtration chromatography and non-reducing-SDS-PAGE, and the purity was >95% and the recovery rate was >85%.
[0082] Example 5
[0083] Biological activity detection of recombinant human type III collagen COLIII-20:
[0084] 1. MTT method was used to measure the effect of recombinant human type III collagen on the proliferation of mouse embryonic fibroblasts and human immortalized epidermal cells:
[0085] (1) Mouse embryonic fibroblasts NIH / 3T3 or human immortalized epidermal cells HaCaT were digested, centrifuged, resuspended, and diluted to 3×10 4 Each well was inoculated with 100 μL of cell culture medium into a 96-well cell culture plate. At the same time, a culture medium without cells was inoculated as a blank control. The cells were cultured at 37°C, 5% CO2, and 95% humidity for 24 h.
[0086] (2) Prepare COLIII-20 protein suspensions at 0.5 mg / mL, 0.25 mg / mL, 0.125 mg / mL, 0.0625 mg / mL, 0.03125 mg / mL, and 0.015625 mg / mL.
[0087] (3) The culture medium was discarded, and the blank control was added with culture medium, the negative control was added with culture medium, the positive control was added with culture medium containing 5% DMSO, and the experimental group was added with culture medium containing different concentrations of COLIII-20 protein solution. The cells were cultured at 37°C, 5% CO2, and 95% humidity for 24 h.
[0088] (4) Add 20 μL MTT to each well and incubate in an incubator for 4 h at 37°C, 5% CO2, and 95% humidity. Add 150 μL DMSO and incubate on a shaker for 10 min to fully dissolve the crystals. Detect the absorbance at 490 nm using an ELISA reader.
[0089] Test results such as Figure 4 As shown. Figure 4 A and B show that: taking the negative control group as 100%, the survival rate of the NIH / 3T3 experimental group supplemented with COLIII-20 was 124%; and the survival rate of the HaCaT experimental group supplemented with COLIII-20 was 135%.
[0090] 2. Scratch test to measure the effect of recombinant human type III collagen on the migration of “human immortalized epidermal cells”:
[0091] (1) Cell culture: Use a marker pen to draw 5 horizontal lines on the back of each well of a 6-well plate, with each line spaced approximately 0.5 cm apart as markers. Use HaCaT cells to set up a blank group, a control group, and an experimental group. After digestion, centrifugation, and resuspension, dilute to 2×10 6 Each well was 2 mL of cell suspension to ensure that the cell density of each group was the same and that the confluence reached 95-100% after 24 h of culture.
[0092] (2) Scratch test: After 24 hours of cell culture, a 200 μL pipette tip was used to scratch the cell layer vertically close to the culture plate surface to form a scratch. The cells were rinsed with PBS three times, the scratched cells were removed, and 2 mL of culture medium containing COLIII-20 protein was added to 6 wells respectively, with a final concentration of 0.05 mg / mL, 0.005 mg / mL, and 0.0005 mg / mL. The blank group was only added with culture medium. The control group was added with commercially available recombinant collagen.
[0093] (3) The cells were cultured in an incubator at 37°C, 5% CO2, and 95% humidity, and microscopic photography was performed at a fixed position after 0 h, 24 h, and 48 h.
[0094] (4) Use Image J to measure the scratch area: Use the software to process the scratch images (0h, 24h / 48h) and finally obtain the cell migration rate.
[0095] Test results such as Figure 5 As shown. Figure 5A and B show that the 24h migration rate of the blank control group (NC) was 10%, and the 48h migration rate was 13%; the 24h migration rate of the commercially available recombinant collagen was 17%, and the 48h migration rate was 20%; the 24h migration rate of the experimental group added with 0.0005mg / mL COLIII-20 was 25%, and the 48h migration rate was 37%.
[0096] Example 6
[0097] Fermentation of recombinant Pichia pastoris (expressing COLIII-20 protein) in a 5L fermenter:
[0098] (1) Seed culture
[0099] Pick a single colony of fresh Pichia yeast on the YPD plate, inoculate it into a 50 mL centrifuge tube containing 5 mL BMGY medium, and culture it at 30 ° C, 240 rpm for 18-24 h; transfer it to a 1 L shake flask containing 200 mL BMGY seed medium at a 2% inoculum amount, and culture it at 30 ° C, 240 rpm for 14-18 h until the OD 600 = 5 to 6. With an inoculation volume of 10%, 200 mL of seed culture solution was inoculated into a 5 L fermentation tank (containing 2 L of BSM basal salt medium).
[0100] (2) Fermentation culture
[0101] During the glycerol culture stage, the temperature was maintained at 30°C, pH 5.0, the speed was adjusted to 400-800rpm, and DO>20%. When the glycerol in the BSM medium was exhausted, DO = 70-80, and the glycerol addition stage was entered. 50% glycerol was added to further increase the cell density. When the wet weight of the cells was about 180-220g / L, the starvation period began. After starvation for 1 hour, the methanol addition period began. The induction temperature was adjusted to 26°C, and methanol was added to maintain DO at about 20%. Ammonia and phosphoric acid were used to maintain pH throughout the fermentation process. After 54 hours of induction, the tank was released and the supernatant was collected by centrifugation.
[0102] The growth curve of COLIII-20 fermentation bacteria and target protein expression in a 5L fermenter is shown in the figure. Figure 6 As shown. Figure 6 It can be seen that after 24 hours of induction, the COLIII-20 production has reached 0.67g / L; after 54 hours of induction, the highest COLIII-20 production is 0.97g / L.
[0103] In summary, the recombinant human type III collagen COLIII-20 of the present invention has a small molecular weight, contains two GER and one GEK integrin recognition sites, and has excellent activity. It not only has an excellent effect of promoting cell proliferation in mouse embryonic fibroblasts, but also has an excellent effect of promoting cell proliferation and migration in human immortalized epidermal cells. It can be widely used in wound repair materials, medical cosmetic surgery, cosmetics, health care products and other fields, especially has good application prospects in skin damage.
[0104] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.
Claims
1. A recombinant human type III collagen, characterized in that: The amino acid sequence is shown in SEQ ID NO.
2.
2. A recombinant human type III collagen encoding gene, characterized in that: The gene encodes the recombinant human type III collagen as described in claim 1, and the nucleotide sequence is shown in SEQ ID NO.
1.
3. The recombinant human type III collagen encoding gene according to claim 2, characterized in that: The nucleotide sequence shown in SEQ ID NO.1 is a codon-optimized sequence adapted to the Pichia pastoris expression system.
4. The recombinant human type III collagen encoding gene according to claim 3, characterized in that: Online codon optimization software was used to change the corresponding original recombinant human type III collagen codon bases to the bases preferred by Pichia pastoris codons without changing the protein coding sequence.
5. An expression vector, characterized in that: It comprises the recombinant human type III collagen encoding gene as described in any one of claims 2 to 4.
6. The expression vector according to claim 5, characterized in that The expression vector is constructed by adding an EcoRI restriction site sequence to the 5' end of the coding gene sequence and a stop codon and NotI restriction site sequence to the 3' end; then, the sequence fragment is inserted into the pPIC9K expression vector through the EcoRI and NotI restriction sites to obtain the corresponding recombinant expression vector.
7. A recombinant Pichia pastoris engineered bacterium, characterized in that: It comprises the recombinant human type III collagen encoding gene as described in any one of claims 2 to 4.
8. The engineered bacteria according to claim 7, characterized in that: The construction method of the engineering bacteria is as follows: the expression vector constructed by the recombinant human type III collagen coding gene is linearized and then transferred into Pichia pastoris GS115.
9. A method for preparing recombinant human type III collagen as claimed in claim 1, characterized in that: The steps include: (1) synthesizing the nucleotide sequence encoding the recombinant human type III collagen single chain shown in SEQ ID NO.1; (2) Designing PCR primers to amplify a DNA fragment encoding a single-chain recombinant human type III collagen, the primers are shown in SEQ ID NO.3 and SEQ ID NO.4; (3) constructing a recombinant expression vector comprising the DNA fragment encoding the recombinant human type III collagen single chain, wherein the expression vector is pPIC9K; (4) After linearization, the constructed expression vector was transformed into Pichia pastoris GS115 to obtain recombinant Pichia pastoris engineered bacteria; (5) culturing the above-mentioned recombinant Pichia pastoris engineered bacteria to express recombinant human type III collagen fragment; (6) Separation and purification of the recombinant human type III collagen fragment expressed in step (5): separation and purification of the recombinant type III collagen using dialysis, ion exchange, and secondary dialysis.
10. Use of the recombinant human type III collagen as claimed in claim 1 in preparing wound repair materials.
